Bacteria producing antimicrobials against Clostridium difficile isolated from human stool

Khattab, Rania Abdelmonem; Ahmed, Noha Ahmed Abd Alfadil; Ragab, Yasser; Rasmy, Salwa A.

doi:10.1016/j.anaerobe.2020.102206

Cited by 6 publications

(8 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BA PMC-80 was isolated from traditional fermented food and confirmed as B. amyloliquefaciens using a biochemical profile, 16S rRNA gene sequencing, and phylogenetic analysis. The results of our identification experiments are similar to those of several recent and previous articles [ 35 , 39 ].…”

Section: Discussionsupporting

confidence: 91%

“…Recently, the search for alternative treatments against CDI has gained extraordinary attention. Probiotics have already shown protective effects on CDI and have been included in many trials to recover the imbalance in the gut microbiota resulting from antibiotics [ 35 , 51 , 52 ]. This study provides information on the in vitro activity of a prospective probiotic strain B. amyloliquefaciens PMC-80 against C. difficile and its in vivo efficacy in a CDI hamster model.…”

Section: Discussionmentioning

confidence: 99%

“…Bacillus amyloliquefaciens (BA), a potential candidate and member of the Bacillus genus, has been suggested in several recent studies to produce antimicrobial peptides [ 27 ], antibiotic compounds such as difficidin and bacilysin [ 30 , 31 ], antifungal protein baciamin [ 32 , 33 ] and antifungal iturin/fengycin-like peptides [ 34 ]. BA is also known to exert a beneficial effect on CDI-associated diarrheal diseases [ 35 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

In Vitro and In Vivo Anti-Clostridioides difficile Effect of a Probiotic Bacillus amyloliquefaciens Strain

Islam

Seo

Asma

et al. 2022

J. Microbiol. Biotechnol.

View full text Add to dashboard Cite

Clostridioides difficile infection (CDI) is a significant cause of hospital-acquired and antibioticmediated intestinal diseases and is a growing global public health concern. Overuse of antibiotics and their effect on normal intestinal flora has increased the incidence and severity of infections. Thus, the development of new, effective, and safe treatment options is a high priority. Here, we report a new probiotic strain, Bacillus amyloliquefaciens (BA PMC-80), and its in vitro/in vivo anti-C. difficile effect as a prospective novel candidate for replacing conventional antibiotics. BA PMC-80 showed a significant anti-C. difficile effect in coculture assay, and its cell-free supernatant (CFS) also exhibited a considerable anti-C. difficile effect with an 89.06 μg/ml 50% minimal inhibitory concentration (MIC) in broth microdilution assay. The CFS was stable and equally functional under different pHs, heat, and proteinase treatments. It also exhibited a high sensitivity against current antibiotics and no toxicity in subchronic toxicity testing in hamsters. Finally, BA PMC-80 showed a moderate effect in a hamster CDI model with reduced infection severity and delayed death. However, further studies are required to optimize the treatment condition of the hamster CDI model for better efficacy and identify the antimicrobial compound produced by BA PMC-80.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In Vitro and In Vivo Anti-Clostridioides difficile Effect of a Probiotic Bacillus amyloliquefaciens Strain

Islam

Seo

Asma

et al. 2022

J. Microbiol. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…However, to date, evidence from clinical trials regarding the potential benefits of probiotics against C. difficile is based exclusively on a few bacterial strains, meaning there is not enough data to generally accept and explain the positive in vivo potential [ 51 , 52 , 53 , 54 ]. In fact, to date, little is known about how the antagonism is established between probiotic bacteria and C. difficile proliferation [ 55 , 56 ]. The study by Khattab et al [ 55 ] revealed Lactobacillus ( L. agilis ), Enterococcus , and Clostridium (mainly, C. butyricum ) genera as having antagonistic potential against C. difficile by synthesis of extracellular thermostable antimicrobials.…”

Section: Natural Antimicrobials Against Clostridioides Difficile Infection (Cdi): Nutraceutical and Pharmaceutical Appmentioning

confidence: 99%

“…In fact, to date, little is known about how the antagonism is established between probiotic bacteria and C. difficile proliferation [ 55 , 56 ]. The study by Khattab et al [ 55 ] revealed Lactobacillus ( L. agilis ), Enterococcus , and Clostridium (mainly, C. butyricum ) genera as having antagonistic potential against C. difficile by synthesis of extracellular thermostable antimicrobials.…”

Section: Natural Antimicrobials Against Clostridioides Difficile Infection (Cdi): Nutraceutical and Pharmaceutical Appmentioning

confidence: 99%

Alimentary and Pharmaceutical Approach to Natural Antimicrobials against Clostridioides difficile Gastrointestinal Infection

Tortajada‐Girbés

Rivas

Cedillo-Hernandez

et al. 2021

Foods

View full text Add to dashboard Cite

Incidence of Clostridioides difficile infection (CDI) has been increasing in recent decades due to different factors, namely (i) extended use of broad-spectrum antibiotics, (ii) transmission within asymptomatic and susceptible patients, and (iii) unbalanced gastrointestinal microbiome and collateral diseases that favor C. difficile gastrointestinal domination and toxin production. Although antibiotic therapies have resulted in successful control of CDI in the last 20 years, the development of novel strategies is urged in order to combat the capability of C. difficile to generate and acquire resistance to conventional treatments and its consequent proliferation. In this regard, vegetable and marine bioactives have emerged as alternative and effective molecules to fight against this concerning pathogen. The present review examines the effectiveness of natural antimicrobials from vegetable and algae origin that have been used experimentally in in vitro and in vivo settings to prevent and combat CDI. The aim of the present work is to contribute to accurately describe the prospective use of emerging antimicrobials as future nutraceuticals and preventive therapies, namely (i) as dietary supplement to prevent CDI and reduce CDI recurrence by means of microbiota modulation and (ii) administering them complementarily to other treatments requiring antibiotics to prevent C. difficile gut invasion and infection progression.

show abstract

Potentially probiotic or postbiotic pre-converted nitrite from celery produced by an axenic culture system with probiotic lacticaseibacilli strain

et al. 2021

View full text Add to dashboard Cite

Bacteria producing antimicrobials against Clostridium difficile isolated from human stool

Cited by 6 publications

References 44 publications

In Vitro and In Vivo Anti-Clostridioides difficile Effect of a Probiotic Bacillus amyloliquefaciens Strain

In Vitro and In Vivo Anti-Clostridioides difficile Effect of a Probiotic Bacillus amyloliquefaciens Strain

Alimentary and Pharmaceutical Approach to Natural Antimicrobials against Clostridioides difficile Gastrointestinal Infection

Potentially probiotic or postbiotic pre-converted nitrite from celery produced by an axenic culture system with probiotic lacticaseibacilli strain

Contact Info

Product

Resources

About